BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16563352)

  • 1. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
    Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
    Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
    Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
    Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
    Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in enantioselectivity in bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6.
    Masuda K; Tamagake K; Okuda Y; Torigoe F; Tsuzuki D; Isobe T; Hichiya H; Hanioka N; Yamamoto S; Narimatsu S
    Chirality; 2005 Jan; 17(1):37-43. PubMed ID: 15526337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6.
    Keizers PH; Schraven LH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; van Dijk BR; Vermeulen NP; Commandeur JN
    Biochem Biophys Res Commun; 2005 Dec; 338(2):1065-74. PubMed ID: 16269134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface-enhanced resonance Raman scattering of cytochrome P450-2D6 on coated silver hydrosols.
    Bonifacio A; Keizers PH; Vermeulen NP; Commandeur JN; Gooijer C; van der Zwan G
    Langmuir; 2007 Feb; 23(4):1860-6. PubMed ID: 17279667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
    Hanna IH; Kim MS; Guengerich FP
    Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
    Guengerich FP; Hanna IH; Martin MV; Gillam EM
    Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
    Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
    Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
    van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN
    J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
    Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
    Yu A; Dong H; Lang D; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
    Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
    Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
    Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
    Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
    Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation.
    Keizers PH; de Graaf C; de Kanter FJ; Oostenbrink C; Feenstra KA; Commandeur JN; Vermeulen NP
    J Med Chem; 2005 Sep; 48(19):6117-27. PubMed ID: 16162012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
    Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
    Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.